Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07782021 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07782021 · ClinicalTrials.gov record · last posted 2026-08-24

MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease

Name: MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease — clinical trial record (NCT07782021)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MIRICURE

StatusNot Yet Recruiting

PhasePhase 4

SponsorIcahn School of Medicine at Mount Sinai

Started2026-12

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This Phase 4, single-arm, open-label study will evaluate the effectiveness and safety of mirikizumab combined with surgical curettage and closure in adults with active perianal fistulizing Crohn's disease. Fifty participants with complex draining fistulas will undergo staged surgical management followed by mirikizumab induction and maintenance therapy. The primary endpoint is combined clinical remission and radiologic response at Week 24. Participants will be followed through Week 48.

Trial Details

NCT Number	NCT07782021
Lead Sponsor	Icahn School of Medicine at Mount Sinai Collaborators: Eli Lilly and Company, Washington University School of Medicine
Conditions	Crohn's Disease, Perianal Fistula
Enrollment	50 participants
Start Date	2026-12
Primary Completion	2028-12 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-24